Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain ...Middle East

TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") in Portugal, for exclusive rights to the commercialization of clobetasol...

Hence then, the article about formosa pharmaceuticals and davi farmaceutica announce licensing agreement for clobetasol propionate ophthalmic suspension for the treatment of post operative inflammation and pain was published today ( Thursday 31/10/2024 - 04:41 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain )

Also on site :

• The Supreme Court Cast Its Lot With Trumpism. It Should Be Very Worried.
• Eight fire crews tackling blaze at West Midlands Wetherspoon pub
• My Wife Doesn’t Know I Watched Her Cheat On Me. My Reaction Might Shock Us Both.